glp-1 layoffs news Novo Nordisk to cut 9,000 jobs to compete in market What's next for GLP-1 innovation:

The main limitations of the use of GLP-1 RAs were related to administrative requirements (#12 and #13), the absence of comprehensive and individualized treatment strategies based on comorbidities of people with T2D (#16), and not considering CV risk as a switching treatment factor (#17)

You can stay within the same general regionsuch as the abdomenas long as each new injection is at least one inch away from the previous one, and this rotation guide for semaglutide and tirzepatide shows how to build a simple system

And it is

Today, Im joined by registered dietitian Ashley Koff, author of Your Best Shot, for an evidence-informed conversation about GLP-1s in midlife

In the STEP UP trial, adults living with obesity who received semaglutide 7.2mg achieved an average weight loss of 18.7% over 72 weeks, compared with 15.6% with 2.4mg and 3.9% with placebo